Advertisement

Animal Models of Multiple Myeloma

  • Sam W. Z. Olechnowicz
  • Claire M. EdwardsEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1914)

Abstract

Multiple myeloma (MM) is a plasma cell neoplasm which is defined by strong interactions with the bone marrow microenvironment, a compartment with high cellular heterogeneity and unique structural and extracellular components. This necessitates the use of in vivo models for research to fully recapitulate MM growth conditions. The selection of appropriate model system is crucial, as each has advantages and shortcomings. Here, we describe the murine models available for studying MM, and focus on the methods for inoculating mice with MM cells via intravenous, intratibial or subcutaneous delivery, as well as monitoring of disease and organ processing for further analysis. The interaction and destruction of bone is a hallmark symptom of MM, and therefore many other complementary techniques used in calcified tissue research can be used, such as microCT, histomorphometry, and biomechanical testing.

Key words

Multiple myeloma Murine model Bone disease Tumor Osteoclast Osteoblast In vivo 

References

  1. 1.
    Kyle RA, Durie BGM, Rajkumar SV et al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121–1127CrossRefGoogle Scholar
  2. 2.
    Olechnowicz SWZ, Edwards CM (2014) Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res 74:1625–1631CrossRefGoogle Scholar
  3. 3.
    Garrett IR, Dallas S, Radl J, Mundy GR (1997) A murine model of human myeloma bone disease. Bone 20:515–520CrossRefGoogle Scholar
  4. 4.
    Manning LS, Berger JD, O’Donoghue HL et al (1992) A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer 66:1088–1093CrossRefGoogle Scholar
  5. 5.
    Vanderkerken K, De Raeve H, Goes E et al (1997) Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 76:451–460CrossRefGoogle Scholar
  6. 6.
    Lwin ST, Olechnowicz SWZ, Fowler JA, Edwards CM (2015) Diet-induced obesity promotes a myeloma-like condition in vivo. Leukemia 29:507–510CrossRefGoogle Scholar
  7. 7.
    Fowler JA, Mundy GR, Lwin ST, Edwards CM (2012) Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res 72:2183–2189CrossRefGoogle Scholar
  8. 8.
    Amend SR, Wilson WC, Chu L et al (2015) Whole genome sequence of multiple myeloma-prone C57BL/KaLwRij mouse strain suggests the origin of disease involves multiple cell types. PLoS One 10:e0127828CrossRefGoogle Scholar
  9. 9.
    Noll JE, Hewett DR, Williams SA et al (2014) SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia 16:572–585CrossRefGoogle Scholar
  10. 10.
    Fowler J a, Mundy GR, Lwin ST et al (2009) A murine model of myeloma that allows genetic manipulation of the host microenvironment. Dis Model Mech 2:604–611CrossRefGoogle Scholar
  11. 11.
    Mori Y, Shimizu N, Dallas M et al (2004) Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104CrossRefGoogle Scholar
  12. 12.
    Lawson MA, Paton-Hough JM, Evans HR et al (2015) NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease. PLoS One 10:e0119546CrossRefGoogle Scholar
  13. 13.
    Hjorth-Hansen H, Seifert MF, Börset M et al (1999) Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 14:256–263CrossRefGoogle Scholar
  14. 14.
    Cocco C, Giuliani N, Di Carlo E et al (2010) Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res 16:4188–4197CrossRefGoogle Scholar
  15. 15.
    Mitsiades CS, Mitsiades NS, Bronson RT et al (2003) Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 63:6689–6696PubMedGoogle Scholar
  16. 16.
    Bartee E, Chan WM, Moreb JS et al (2012) Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant 18:1540–1551CrossRefGoogle Scholar
  17. 17.
    Wu K-D, Zhou L, Burtrum D et al (2006) Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 56:343–357CrossRefGoogle Scholar
  18. 18.
    Miyakawa Y, Ohnishi Y, Tomisawa M et al (2004) Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun 313:258–262CrossRefGoogle Scholar
  19. 19.
    Pilarski LM, Hipperson G, Seeberger K et al (2000) Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95:1056–1065PubMedGoogle Scholar
  20. 20.
    Das R, Strowig T, Verma R et al (2016) Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat Med 22:1351–1357CrossRefGoogle Scholar
  21. 21.
    Urashima M, Chen BP, Chen S et al (1997) The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 90:754–765PubMedGoogle Scholar
  22. 22.
    Yata K, Yaccoby S (2004) The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18:1891–1897CrossRefGoogle Scholar
  23. 23.
    Calimeri T, Battista E, Conforti F et al (2011) A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 25:707–711CrossRefGoogle Scholar
  24. 24.
    Lwin ST, Edwards CM, Silbermann R (2016) Preclinical animal models of multiple myeloma. Bonekey Rep 5:772CrossRefGoogle Scholar
  25. 25.
    Paton-Hough J, Chantry AD, Lawson MA (2015) A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease. Bone 77:57–68CrossRefGoogle Scholar
  26. 26.
    Oyajobi BO, Muñoz S, Kakonen R et al (2007) Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 6:1701–1708CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Nuffield Department of Surgical SciencesUniversity of OxfordOxfordUK
  2. 2.Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research CentreUniversity of OxfordOxfordUK

Personalised recommendations